These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 21338196

  • 1. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S, Zafar A, Saperi S, Amrizal M.
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [Abstract] [Full Text] [Related]

  • 2. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S, Gasparini R, Panatto D, Demarteau N.
    Gynecol Oncol; 2011 Jun 01; 121(3):514-21. PubMed ID: 21334734
    [Abstract] [Full Text] [Related]

  • 3. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, Lee IH.
    Asian Pac J Cancer Prev; 2018 Apr 25; 19(4):933-940. PubMed ID: 29693347
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.
    Value Health; 2012 May 07; 15(5):622-31. PubMed ID: 22867770
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.
    Vaccine; 2015 May 07; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [Abstract] [Full Text] [Related]

  • 8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA, Lepetic A, Demarteau N.
    BMC Public Health; 2014 Nov 26; 14():1222. PubMed ID: 25424716
    [Abstract] [Full Text] [Related]

  • 10. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 11. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, Wang W, Palmer C.
    J Med Econ; 2023 Sep 01; 26(1):1085-1098. PubMed ID: 37608730
    [Abstract] [Full Text] [Related]

  • 12. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 13. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E, Fröberg M, Leval A, Hellström AC, Bäcklund M, Zethraeus N, Andersson S.
    PLoS One; 2015 Aug 20; 10(9):e0139062. PubMed ID: 26398189
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2007 Mar 23; 56(RR-2):1-24. PubMed ID: 17380109
    [Abstract] [Full Text] [Related]

  • 17. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
    Lee H, Hur S, Jang H, Lee IH, Sohn WY, Van Kriekinge G, Kim BG.
    Asian Pac J Cancer Prev; 2019 Feb 26; 20(2):425-435. PubMed ID: 30803204
    [Abstract] [Full Text] [Related]

  • 18. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N.
    Vaccine; 2014 Feb 03; 32(6):733-9. PubMed ID: 24291200
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

  • 20. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW, Aljunid S.
    Asian Pac J Cancer Prev; 2010 Mar 31; 11(4):943-51. PubMed ID: 21133606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.